These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30605282)

  • 1. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K; Punyapornwithaya V; Tankaew P; Pongkan W; Chattipakorn N; Boonyapakorn C
    Pol J Vet Sci; 2018 Dec; 21(4):673-680. PubMed ID: 30605282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
    Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K; Riengvirodkij N; Channgam P; Kaenchan P; Buayam W; Janhirun Y; Phonarknguen R; Tansakul M; Sakcamduang W
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M; Hori Y; Kanno N; Iwasa N; Toyofuku T; Isayama N; Yoshikawa A; Akabane R; Sakatani A; Miyakawa H; Hsu HH; Miyagawa Y; Takemura N
    J Vet Med Sci; 2021 Apr; 83(4):705-715. PubMed ID: 33551383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages.
    Thassakorn P; Patchanee P; Pongkan W; Chattipakorn N; Boonyapakorn C
    J Vet Pharmacol Ther; 2019 May; 42(3):258-267. PubMed ID: 30666669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of natriuretic peptides in dogs with mitral valve disease.
    Tarnow I; Olsen LH; Kvart C; Hoglund K; Moesgaard SG; Kamstrup TS; Pedersen HD; Häggström J
    Vet J; 2009 May; 180(2):195-201. PubMed ID: 18675567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease.
    Winter RL; Saunders AB; Gordon SG; Buch JS; Miller MW
    J Vet Cardiol; 2017 Apr; 19(2):124-131. PubMed ID: 28111138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations in dogs with mitral valve insufficiency.
    Takemura N; Toda N; Miyagawa Y; Asano K; Tejima K; Kanno N; Arisawa K; Kurita T; Nunokawa K; Hirakawa A; Tanaka S; Hirose H
    J Vet Med Sci; 2009 Jul; 71(7):925-9. PubMed ID: 19652480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration.
    Ruaux C; Scollan K; Suchodolski JS; Steiner JM; Sisson DD
    Vet Clin Pathol; 2015 Sep; 44(3):420-30. PubMed ID: 26108974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ; Block CL; Laughlin DS; Oyama MA
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma atrial natriuretic peptide is an early diagnosis and disease severity marker of myxomatous mitral valve disease in dogs.
    Ebisawa T; Ohta Y; Funayama M; Yamano S; Mizuno M; Mizuno T; Kasuya A; Sawada T; Lee J; Mizukoshi T; Uechi M
    Res Vet Sci; 2013 Jun; 94(3):717-21. PubMed ID: 23312500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B.
    Jang IS; Yoon WK; Choi EW
    Ir Vet J; 2023 Feb; 76(1):3. PubMed ID: 36755290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
    BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease.
    Chetboul V; Serres F; Tissier R; Lefebvre HP; Sampedrano CC; Gouni V; Poujol L; Hawa G; Pouchelon J-
    J Vet Intern Med; 2009; 23(5):984-94. PubMed ID: 19572913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease.
    Höglund K; Häggström J; Höglund OV; Stridsberg M; Tidholm A; Ljungvall I
    Acta Vet Scand; 2020 Aug; 62(1):43. PubMed ID: 32758260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays.
    Winter RL; Saunders AB; Gordon SG; Miller MW; Fosgate GT; Suchodolski JS; Steiner JM
    Vet Clin Pathol; 2017 Jun; 46(2):299-307. PubMed ID: 28449360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation and its association with oxidative stress in dogs with heart failure.
    Nemec Svete A; Verk B; Čebulj-Kadunc N; Salobir J; Rezar V; Domanjko Petrič A
    BMC Vet Res; 2021 Apr; 17(1):176. PubMed ID: 33902566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
    Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
    PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.